This “ Journal Watch ” discusses “ Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout, ” published in The New England Journal of Medicine, 2018 . Authors - William B. White et al.
Highlights Cardiovascular risk is increased in patients with gout This study compared cardiovascular outcomes associated with febuxostat with those associated with allopurinol in patients with gout and cardiovascular disease Cardiovascular mortality rate was higher with febuxostat than with allopurinol in patients with gout and having major cardiovascular coexisting conditions Key takeaways Febuxostat is associated with higher all-cause mortality and cardiovascular mortality rates than allopurinol in patients with gout. Objective: To determine whether febuxostat was non-inferior to allopurinol with respect to rates of adverse cardiovascular events in patients with gout and…
